Sogroya is administered by subcutaneous injection once weekly. The Food and Drug Administration (FDA) has approved Sogroya ® (somapacitan-beco) for the treatment of pediatric patients aged 2.5 years ...
Pfizer PFE along with partner OPKO Health OPK announced that the FDA has approved Ngenla (somatrogon) as a once-weekly treatment for pediatric patients aged three years and older with growth hormone ...
Results demonstrated that once weekly somapacitan-beco is noninferior to daily somatropin injections for improving annualized height velocity in children with NS, ISS, and those born SGA. The Food and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results